1 / 21

HOMELAND DEFENSE CONFERENCE WASHINGTON, DC. MARCH 30, 2004

Aethlon Medical is pioneering the development of viral filtration devices that rapidly reduce the presence of viruses and toxins in the blood..

medea
Download Presentation

HOMELAND DEFENSE CONFERENCE WASHINGTON, DC. MARCH 30, 2004

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. Presenter: James A. Joyce Chairman and CEO This presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when new products are successfully developed and introduced by the Company, market acceptance of current or new products, regulatory delays, manufacturing delays, and other risks which may be detailed in Aethlon Medical’s SEC filings. HOMELAND DEFENSE CONFERENCE WASHINGTON, DC. MARCH 30, 2004

    2. Aethlon Medical is pioneering the development of viral filtration devices that rapidly reduce the presence of viruses and toxins in the blood.

    3. The HemopurifierTM Hemodialysis Affinity Chromatography

    4. HemopurifierTM Advantages Mimics Immune Response Antibody Immobilization Fusion/Entry Inhibitor Multiple Disease Treatment Established Infrastructure

    5. HemopurifierTM Markets Biological Weapons HIV/AIDS Hepatitis-C (HCV)

    7. Biological Weapon Targets CDC CATEGORY “A” AGENTS Smallpox Viruses Anthrax Bacterium Botulinum Toxin Hemorrhagic Fevers Ebola Marburg Septic Shock Mediators Genetically Engineered

    8. Bioterrorism Challenges Vast Number of Targets Genetic Engineering Vaccine & Drug Limitations Pathogens are Inexpensive & Accessible Easy to Deliver

    9. Hemopurifier Advantages Adjunctive Sole Solution Rapid Development & Deployment Addresses Military & Civilian Requirements

    10. National Center for Biodefense U.S. Military - Countermeasures Against Biological Weapons Improves Access to Government Grants & Contracts Increases Scientific Resources, Advocates Charles Bailey, MD. Ken Alibek, MD.

    11. The Aethlon Science Team

    12. Richard Tullis, Ph.D. Developer of Infectious Disease and Biowarfare Hemopurifiers. Inventor and original patent holder of Antisense, and related DNA synthesis technologies. Co-founder and Director of Research of Molecular Biosystems (NYSE). Founder of Synthetic Genetics, Inc., and Syngen Research, Inc.

    13. Kenneth Michael, Ph.D. Founder, Past President & Chairman of The Regulatory Affairs Professionals Society (RAPS), an 8000 member International Regulatory Affairs Organization. Director of Regulatory Affairs at Siemens Medical Systems.

    14. Nathan W. Levin, MD Medical and Research Director of the Renal Research Institute, LLC. Professor of Clinical Medicine at the Albert Einstein College of Medicine.

    15. Claudio Ronco, MD Director of the Dialysis and Renal Transplantation at St. Bartolo Hospital in Vicenza, Italy. Instrumental in the introduction of continuous hemofiltration and high flux dialysis in Europe. Seventeen books on nephrology and dialysis. 350+ scientific papers. Editorial board of twelve scientific journals. Director of three international scientific societies.

    16. Larry Cowgill, D.V.M., Ph.D. Professor in the Department of Medicine and Epidemiology at the School of Veterinary Medicine, University of California. Head of companion animal dialysis at the Veterinary Medical Teaching Hospital at UC Davis and the UC Veterinary Medical Center-San Diego. Leading authority in managing animal dialysis clinical programs.

    17. Raveendran Pottathil, Ph.D. Former Section Director of Retroviral Research at Hoffman La Roche. Advisor to World Health Organization’s Sexually Transmitted Diseases and Global Vaccination Program. Co-founder of Specialty Biosystems, Inc. President of AccuDx, Inc.

    18. Jean-Claude Chermann, Ph.D. AIDS virus discoverer. Director of Research of the Pasteur Institute. Director of Research of INSERM (French National Institute of Health and Medical Research). First to demonstrate that HIV is a retrovirus. First use of HIV anti-retroviral agent in humans. First to demonstrate HIV infection in US patients through the detection of antibodies.

    19. Pedro Cuatrecasas, MD Inventor of Affinity Chromatography. Former President of Pharmaceutical Research at Parke-Davis. Corporate Vice President for Warner Lambert Company. Senior Vice President and Director of Glaxo Inc. Vice President, R&D, and Director, of Burroughs Wellcome. Involved in the commercialization of over forty novel medicines. Member of the National Academy of Sciences, The Institute of Medicine, American Academy of Arts & Sciences. Numerous awards, including The Wolf Prize in Medicine. 400+ scientific publications.

    20. Targeted 12-Month Value Drivers Introduction of Aethlon to the Financial Industry Partnerships Biowarfare Animal Data Human Trial Initiation Grant Income

    21. Investment Data OTCBB: “AEMD” Stock Price (3/26/04): $1.85 Market Capitalization (3/26/04) : $16.9 million Shares Outstanding (2/12/04): 9,122,711

    22. Conclusion

More Related